Browse News
Filter News
Found 651,048 articles
-
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
2/27/2021
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, March 5, 2021 at 8:30 a.m.
-
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.
-
The U.S. FDA approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 skipping.
-
On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.
-
Funds will be used to support the development of its lead asset, AB-101, an ADCC enhancer NK-cell therapy for use in combination with monoclonal antibodies or innate-cell engagers.
-
After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.
-
Perceptive Advisors’ ARYA Sciences Acquisition IV Raises $130 Million in IPO
2/26/2021
Perceptive Advisors’ fourth healthcare blank check company ARYA Sciences Acquisition IV announced it has raised up to $130 million through the offering of 13 million shares at $10.
-
BioSpace Movers & Shakers, Feb. 26
2/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
The world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms (called shrooms or magic mushrooms) and other plant-based psychedelics recently opened in Jamaica.
-
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial
2/26/2021
Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX)
-
Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
2/26/2021
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company's single-shot COVID-19 vaccine
-
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A
2/26/2021
Today, the U.S. Food and Drug Administration approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death.
-
FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
2/26/2021
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration, FDA, has approved PEPAXTO® (
-
FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting
2/26/2021
Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization
-
Health Canada authorizes AstraZeneca and Verity Pharmaceuticals Inc./Serum Institute of India COVID-19 vaccines
2/26/2021
Today, Health Canada authorized two vaccines; the COVID-19 vaccine manufactured by AstraZeneca, and developed in partnership with Oxford University, and, the Serum Institute of India's version of the AstraZeneca vaccine.
-
RGF® Environmental Group Releases Independent Test: PHI-PKG14 PHI-CELL® Inactivates greater than 99.9% of SARS-CoV-2 Virus in the Air and on Surfaces
2/26/2021
RGF® Environmental Group, Inc., a leading environmental design and manufacturing company, has released the results of an independent, third-party test that indicates the PHI-PKG14 PHI-CELL® product with Photohydroionization® technology inactivates greater than 99.9% of the SARS-CoV-2 virus in the air and on inoculated surfaces.
-
MatMaCorp's COVID-19 2SF RNA Test Effective in Detecting Variants
2/26/2021
MatMaCorp (Materials and Machines Corporation), a developer of comprehensive molecular diagnostic systems, today announced data demonstrating the effectiveness of the company’s COVID-19 2SF RNA test in detecting variants associated with SARS-CoV-2, the virus causing COVID-19.
-
Canada to receive 2 million doses of AstraZeneca's COVID-19 vaccine manufactured by the Serum Institute of India
2/26/2021
The Government of Canada is taking steps to ensure more people in Canada are vaccinated more quickly, and continues to work to give Canadians access to safe and effective COVID-19 vaccines as soon as possible
-
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
2/26/2021
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.